Ipsen Biopharmaceuticals has entered an exclusive three-year agreement with Saol Therapeutics to promote Dysport (abobotulinumtoxinA), a therapy indicated for injection in adults with spasticity and in children with lower limb spasticity – common in amyotrophic lateral sclerosis (ALS) patients. Under the agreement, Saol will set up a…
Speech-language pathologists (SLPs) or speech-language therapists (SLTs) do much more than help people with speech problems such as stuttering or mispronouncing words. For children and adults with neuromuscular disorders like spinal muscular atrophy (SMA), muscular dystrophy (MD) and amyotrophic lateral…
Worldwide Clinical Trials was selected as the Clinical Research Organization (CRO) to run a Phase 3 study of the investigational stem-cell therapy NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm Cell Therapeutics, which developed NurOwn, expects the collaboration will provide all of the necessary requirements to pursue the placebo-controlled,…
Mitsubishi Tanabe Pharma America (MT Pharma America) has enrolled more than 700 sites of care in its newly created National Infusion Center Directory to help physicians identify local infusion centers for amyotrophic lateral sclerosis (ALS) patients who are prescribed Radicava (edaravone).
Military veterans are twice as likely to develop amyotrophic lateral sclerosis (ALS) as those who haven’t served in the military. MORE: Explaining the progression of ALS Despite extensive research into the topic, scientists are still unable to find the link between serving in the military and developing ALS.  According to the…
https://www.youtube.com/watch?v=FvC5KheFWG8 This video from Patients Like Me is all about Cris, who is a mother, grandmother, and great-grandmother. Cris also has amyotrophic lateral sclerosis (ALS). She was diagnosed two years ago but hasn’t had the time to sit around and get depressed about her diagnosis. In between spending time with…
Researchers have slowed the progression of an ALS-like disease in mice, and prolonged their lives, by reducing the activity of a protein receptor that helps transmit signals between nerve cells. The study, which involved the metabotropic glutamate receptor 5, or mGluR5, was published in the journal Neuropharmacology. The article was titled “…
Radicava (edaravone), the first approved treatment for amyotrophic lateral sclerosis in 22 years, is being welcomed with “a great deal of excitement” in the ALS community, an ALS Association executive said. The excitement stems both from Radicava’s potential to treat the disease and the hope that its approval will lead…
Below is a transcript of the ALS News Today interview with Calaneet Balas, executive vice president of strategy for the ALS Association. The nonprofit association, established in 1985, is active in promoting research into ALS, providing assistance to patients through its network of 39 state chapters, and in coordinating care though its…
Edaravone — now more widely known by its U.S. brand name, Radicava — has produced “a minor miracle” for some amyotrophic lateral sclerosis patients, said Stephen Byer, co-director of ALS Worldwide. “We have found and continue to find great benefit in terms of slowing, stopping and, in some…
Get regular updates to your inbox.
